ArticleFrontiers in neuroscience2026
DIA-based serum proteomics of the complement-coagulation cascade identifies candidate biomarkers for myasthenia gravis.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to analyze serum protein changes in patients with myasthenia gravis (MG) via proteomics to identify and validate potential biomarkers. Methods: Serum samples were collected from 10 MG patients and 10 healthy controls. The data-independent acquisition (DIA) quantitative proteomics technique was used to measure serum protein levels and identify differentially expressed proteins. Functional enrichment analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA), were performed to determine the enrichment trends of the differentially expressed proteins. On the basis of the Results: A total of 220 proteins met the exploratory nominal differential-expression criteria between the MG and healthy control groups, including 49 upregulated and 171 downregulated proteins. After Benjamini-Hochberg FDR correction, 138 proteins remained statistically significant, including 23 upregulated and 115 downregulated proteins. Pathway analysis suggested enrichment of complement/coagulation cascades, tight junctions, regulation of the actin cytoskeleton, and Rap1 signaling. Five prioritized proteins-PROS1, PROC, C4BPA, PFN1, and TLN1-were further evaluated by PRM and ELISA. PRM supported their differential abundance and pathway-level association with complement/coagulation regulation and cytoskeleton-related processes, but did not demonstrate a causal damage cascade. ROC analysis showed AUC values greater than 0.8 in this exploratory cohort; however, these estimates should be interpreted cautiously because of the limited sample size. ELISA validation further supported increased PROS1, PROC, and C4BPA levels and decreased PFN1 and TLN1 levels in MG patients compared with controls. Conclusion: PROS1, PROC, C4BPA, PFN1, and TLN1 represent exploratory candidate serum biomarkers for AChR-positive MG and require validation in larger, multicenter cohorts before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.